COVID-19 prevalence during pregnancy and pregnancy outcomes in low resource settings
Not Applicable
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/08/027218
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 5206
Inclusion Criteria
All women in the Maternal Newborn Health Registry will be eligible to be screened for the COVID-19 study at time of enrollment into the MNHR. This study will follow the same inclusion and exclusion criteria as the MNH Registry (MNHR) to screen
Pregnant women intending to deliver within study cluster
Exclusion Criteria
Decline to provide consent to include data in the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of COVID-19 antibody positive results during pregnancyTimepoint: Up to 42 days postpartum
- Secondary Outcome Measures
Name Time Method Fetal/neonatal outcomes: spontaneous abortion, stillbirth, birth weight and fetal growth restriction, early (7-day) and late (28-day) neonatal death, cause of death, congenital infections, and malformationsTimepoint: Up to 42 days postpartum;Knowledge, attitudes, and practices of pregnant women related to COVID-19 infection during pregnancyTimepoint: Up to 42 days postpartum;Maternal outcomes: rate of infection, timing of infection, types of symptoms, death, cause of deathTimepoint: Up to 42 days postpartum